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ABSTRACT
Non-radiographic axial spondyloarthritis (nr-
axSpA) is a recently described form of axial
inflammatory arthritis that has not caused
substantial erosive damage to the sacroiliac
joints. Nr-axSpA is associated with significant
impairment in quality of life and, in a pro-
portion of patients, it can evolve into anky-
losing spondylitis (AS, also termed
radiographic axSpA). The identification in the
clinic of nr-axSpA has been made possible by
advances in magnetic resonance imaging
(MRI). Classification criteria for nr-axSpA have
been proposed but there remains discussion in
the international community regarding this.
Studies are ongoing to further define the clas-
sification and diagnosis of nr-axSpA. There is
much further research required regarding the
optimal use of MRI in nr-axSpA, including
distinguishing sacroiliac MRI changes in the
normal population and the definition of a
positive MRI in spinal disease. Non-steroidal
anti-inflammatory drugs and physiotherapy
are the core first-line therapy for nr-axSpA.
Tumour necrosis factor inhibitors also play a
very important role in treatment of patients
with active nr-axSpA who do not respond to
first-line therapy. Agents directed at inter-
leukin-17, interleukin-23 and Janus kinase
inhibitors are proving effective in AS with
ongoing and planned studies in nr-axSpA. A
great deal of active research is being under-
taken in classification, imaging and therapy in
nr-axSpA and so the future for improving the
lives of patients with nr-axSpA is promising.
Keywords: Ankylosing spondylitis; Axial
spondyloarthritis; Magnetic resonance imag-
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INTRODUCTION
Non-radiographic axial spondyloarthritis (nr-
axSpA) is an important, albeit recently descri-
bed, member of the spondyloarthritis (SpA)
family of conditions. While ankylosing
spondylitis (AS) has long been a recognised
clinical entity due to the clear radiographic
changes present in the sacroiliac joints (SIJs), it
was recognised that there is often a period
where classic signs and symptoms of axial
inflammatory disease are present in the absence
of radiographic changes in the SIJs fulfilling the
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modified New York criteria [1]. Khan and col-
leagues first described this condition in 1985,
calling it ‘‘spondylitic disease without radiologic
evidence of sacroiliitis’’ [2]. It was subsequently
given the name non-radiographic axial SpA to
recognise that not all cases proceeded to radio-
graphic axSpA/AS [3, 4]. This article is based on
previously conducted studies and does not
contain any studies with human participants or
animals performed by any of the authors.
NOMENCLATURE
The nomenclature has evolved with the recog-
nition of nr-axSpA. AxSpA is an umbrella term
which includes radiographic axSpA (also refer-
red to as AS) and nr-axSpA. Patients can also
have combined features of axial SpA and
peripheral SpA.
CLASSIFICATION
The publication by the European-based Assess-
ment of SpondyloArthritis International Society
(ASAS) of their 2009 axSpA classification criteria
was a significant, and somewhat controversial,
milestone in the genesis of nr-axSpA [3, 4]. The
ASAS group proposed that a patient could be
classified as having axSpA by fulfilling one of
two arms after satisfying the entry criteria of
being less than 45 years old and having greater
than 3 months of chronic back pain. The clini-
cal ‘HLA-B27 arm’ allowed classification on the
basis of a positive HLA-B27 test and two or more
SpA features. These features are inflammatory
back pain, arthritis, heel enthesitis, uveitis,
dactylitis, psoriasis, Crohn’s disease, good
response to non-steroidal anti-inflammatory
drugs (NSAIDs), family history of SpA or an
elevated C-reactive protein (CRP). The imaging
arm allowed classification on the basis of either
a positive magnetic resonance imaging (MRI) or
radiographic sacroiliitis and one or more SpA
features from the aforementioned list. Patients
can be classified as nr-axSpA if they meet this
classification criteria set but their radiographic
SIJ changes are not bilateral grade 2 or unilateral
grade 3 or higher. Patients can therefore be
classified as nr-axSpA on the basis of either a
positive MRI of the SIJ or by fulfilling the HLA-
B27 arm without any objective evidence of axial
inflammatory disease. The latter in particular
has led to some criticism of the criteria [5]. This
has precipitated suggestions for modifications
or improvements [6–11]. There is now a com-
bined effort by the North American SpA group
SPARTAN and the European ASAS group to run
two large studies to further explore classifica-
tion of SpA, termed the CLassification of Axial
SpondyloarthritiS Inception Cohort (CLASSIC)
studies.
It should, however, be noted that the above
are all classification criteria for use in clinical
research and are not diagnostic criteria. As such,
these criteria should not simply be applied in a
clinical setting as making a diagnosis of nr-
axSpA requires exclusion of other potential
causes for the presenting symptoms or findings
(both clinical and imaging).
IMAGING IN NR-AXSPA
The importance of imaging in the diagnosis of
axSpA is well established. However, there has
been a transition from the requirement for
established radiographic abnormalities for
diagnosis to identification of ‘‘inflammatory’’
abnormalities on MRI.
Radiographs in axSpA
Radiographic sacroiliitis is a late feature of
axSpA, often occurring after many years of
typical axial symptoms. Radiographs can only
demonstrate bony changes which appear as a
consequence of previous inflammation and
typically include erosions and sclerosis adjacent
to the joint line. Fulfilling the modified New
York criteria (mNYC) for AS requires radio-
graphic evidence of either bilateral grade 2 or
unilateral grade 3 or 4 SIJ changes [1]. However,
the complex anatomy of the sacroiliac joint
makes interpretation of these radiographs diffi-
cult, with highly variable inter- and intra-rater
reliability, even amongst expert readers [12].
Typical lesions seen at the vertebral level on
the spinal radiographs of axSpA patients are
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erosions, sclerosis, squaring, syndesmophytes
and ankylosis. These changes are thought to
commence with entheseal inflammation
involving the outer fibres of the annulus fibrosis
leading to new bone formation, causing squar-
ing of the vertebra and subsequently formation
of syndesmophytes. In a small number of
patients, the continued development of syn-
desmophytes and subsequent bridging at
numerous levels may lead to the classic ‘bam-
boo spine’ appearance.
Use of scoring systems such as the modified
Stoke Ankylosing Spondylitis Severity Score
(mSASSS) has shown progression at a group
level in the spine to occur at a slow and linear
rate [13]. At an individual patient level, how-
ever, radiographic progression is highly variable
with a study over 12 years showing that up to
25% of axSpA patients show no progression
[14].
MRI in axSpA
The use of MRI for diagnosis of axSpA has been
demonstrated in several studies [15–17]. MRI
scans conducted for diagnosis of axSpA need to
include fat-suppressed image sequences, such as
short tau inversion recovery (STIR) or Dixon
sequences, as these are essential to detect the
typical active inflammatory lesions (bone mar-
row oedema (BMO) or osteitis) seen in axSpA.
Whilst BMO lesions form the basis of ASAS cri-
teria for a positive scan (defined as one area of
BMO on at least two consecutive slices or at
least two areas of BMO on a single slice), lesions
such as capsulitis, enthesitis and synovitis are
also seen [18]. More recent research reinforces
the notion that inflammatory changes on an
MRI should not be used in isolation to diagnose
axSpA. In one study, up to 23% of healthy
individuals and 57% of post-partum women
met ASAS positive MRI criteria [19]. Other
recent studies have shown high rates of BMO
lesions in recreational runners, professional
sports people and army recruits undergoing
physical training [20, 21].
In more established disease, inflammatory
lesions are thought to evolve into fatty lesions,
which can be identified on the T1 sequence.
Whilst these lesions are less specific for axSpA
because of their presence in degenerative disc
disease, research has shown fatty lesions to be
predictive of radiographic progression in axSpA
[22]. The inclusion of spinal lesions seen on an
MRI for diagnosis or classification of axSpA has
yet to be agreed on, but the more corner lesions
seen the more suggestive of axSpA, particularly
in young patients or those with other features
suggestive of axSpA [23].
A typical protocol for MRI scanning would
include oblique scans through the sacroiliac
joint with T1 and fat-suppressed sequences like
STIR, SPUR or Dixon [24]. No contrast is
required for diagnosis as it does not increase the
diagnostic yield [25, 26]. The inflammatory
lesions needed for diagnosis are able to be seen
on the fat-suppressed sequences. While scan-
ning the lumbar, thoracic or cervical spine has
not been shown to increase diagnostic yield for
axSpA substantially it is often important to
investigate the cause of a patient’s back pain
[27]. The advantage of using such a protocol is
the short duration required for the patient to be
in the scanner, but it is important to note that
the lack of axial sequences may prevent detailed
assessment of the presence of associated nerve
root lesions.
The identification of BMO on MRI scans has
been shown to be of prognostic value with a
study showing a strong correlation between the
severity/intensity of osteitis on the baseline MRI
and the subsequent development of radio-
graphic sacroiliitis 8 years later [28]. The extent
of osteitis on an MRI has also shown an asso-
ciation with better responses to tumour necrosis
factor inhibitor (TNFi) therapy [29].
Other MRI sequences, such as diffusion-
weighted imaging, for investigating axSpA have
also been proposed but further research is
required to demonstrate their value [30].
When patients present with typical symp-
toms like inflammatory back pain and their MRI
scans are negative then these can be repeated in
the future. Two recent studies demonstrated
that being HLA-B27 positive and also male
increase the chance that a repeat MRI scan at 3
or 12 months will be positive, but the conver-
sion rate was low 7–14% [31, 32]. A study which
performed SIJ needle biopsies also suggested
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that MRI scans have low sensitivity compared to
histological changes, but SIJ needle biopsies are
not performed in clinical practice so this study’s
conclusions lack generalisability [33].
Other Imaging in axSpA
Computerised tomography (CT) is an ideal
modality for demonstrating structural changes
in axSpA patients. However, the common use of
this scanning technique is limited by its signif-
icant ionising radiation dose for the patient.
Newer low dose CT modalities are being inves-
tigated with promising results [34].
MRI scans are the mainstay of diagnostic
imaging in nr-axSpA allowing earlier diagnosis
than plain radiographs. However, imaging must
not be used in isolation to make the diagnosis of
axSpA. In the correct clinical context, MRI may
also be used to assess levels of disease activity
and thereby guide treatment decisions.
THERAPY IN NR-AXSPA
The pharmacological treatment paradigm of
axSpA has progressed considerably with the
advent of biologic disease-modifying anti-
rheumatic drugs (bDMARDs). These drugs have
exhibited excellent efficacy in patients who do
not respond, or only partially respond, to
NSAIDs. However, NSAIDs and physical therapy
remain the cornerstones of initial treatment for
all patients with axSpA, including those with
nr-axSpA.
Patient symptoms and the presence of extra-
articular manifestations of axSpA, like anterior
uveitis, often drive the initiation and choice of
treatment. For example, patients are more likely
to take NSAIDs and perform stretches during an
acute flare of their condition. In addition,
assessing a patient to identify the presence of
other causes of back pain is essential to ensuring
the correct selection of pharmacotherapy—a
patient may have coexisting degenerative disc
disease or fibromyalgia, which might be opti-
mally treated with analgesia or neuromodula-
tory drugs rather than escalation to bDMARDs
[35–37].
Pharmacotherapy in nr-axSpA can be divided
into analgesia and NSAIDs, conventional syn-
thetic DMARDs (csDMARDs) and bDMARDs.
Non-Steroidal Anti-Inflammatory Drugs
NSAIDs have been used for many years for
patients with axSpA and have been shown to
improve disease activity and function [38, 39].
Both traditional and cyclooxygenase (COX) 2
inhibitors are effective but these agents are
known to be associated with adverse cardio-
vascular, renal and gastrointestinal events
[40, 41]. Patients with inflammatory bowel dis-
ease may need to avoid NSAIDs if they precipi-
tate flares of gastrointestinal symptoms but they
can be used safely in many patients, in discus-
sion with their gastroenterologist [42].
NSAIDs have similar efficacy in nr-axSpA as
they do in AS with an ASAS40 response of 35%
at week 4. This demonstrates that although a
substantial minority have a good response to
NSAIDs there remains a large group who likely
need additional therapy [43].
There remains controversy regarding the
ability of NSAIDs to prevent radiographic pro-
gression. A study by Wanders and colleagues
suggested that regular celecoxib prevented pro-
gression of the disease assessed by radiographs,
compared to those taking celecoxib on an ‘as
required’ basis [44]. However, a more recent
randomised controlled study of diclofenac by
Sieper and colleagues did not demonstrate any
reduction of radiographic progression [45].
Many jurisdictions require the use of one or
two different NSAIDs prior to being authorised
to prescribe bDMARDs for patients with active
axSpA. NSAIDs are effective for the majority of
axSpA patients and should therefore be used as
first-line pharmacotherapy, unless contraindi-
cations exist. It is also worth noting that most
axSpA patients stop NSAIDs once they com-
mence bDMARDs. However, studies have
shown an added benefit of combining NSAIDs
and bDMARDs, so NSAIDs should be considered
in those with a suboptimal response to
bDMARDs alone [38].
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Corticosteroids
Corticosteroids are rarely effective for axSpA.
One study showed that relatively high doses of
prednisolone (50 mg) daily was required for an
effective response [46]. Targeted local steroid
injections can often be effective for peripheral
joint and entheseal involvement and have been
shown to be effective for SIJ pain [47]. Topical
and oral steroids are often used to treat flares of
extra-articular manifestations, such as flares of
uveitis or inflammatory bowel disease.
Conventional Synthetic Disease-
Modifying Drugs
Conventional synthetic disease-modifying
drugs (csDMARDs) such as methotrexate or
sulfasalazine have not been shown to be effec-
tive for axial disease [48, 49]. In some countries,
where funding limits the use or availability of
bDMARDs, csDMARDs are often used as first-
line therapy. csDMARDs do, however, have a
role in axSpA patents with peripheral disease,
where they have been shown to be effective
[50]. At present, there is little evidence to sug-
gest that combined csDMARD and bDMARD
therapy is more effective than bDMARD
monotherapy in axSpA.
TNF Inhibitors
TNFi have transformed the treatment paradigm
in nr-axSpA as prior to their initiation many
patients relied on NSAIDs only, which were not
effective in all patients and led to complications
as a result of chronic use. Following the suc-
cessful trials of TNFi in rheumatoid arthritis
(RA), their effectiveness in axSpA was investi-
gated, with favourable results, in AS and subse-
quently in nr-axSpA [51]. These drugs are,
however, expensive with potential side effects,
and therefore several guidelines have been for-
mulated to guide prescription by rheumatolo-
gists [52–54]. Table 1 shows the results of
clinical trials of TNFi in nr-axSpA [55–58].
Adalimumab, etanercept, certolizumab,
golimumab and infliximab are licenced for, and
widely used, in AS. Adalimumab, certolizumab,
etanercept and golimumab have indications for
nr-axSpA in Europe, while etanercept and goli-
mumab have indications for nr-axSpA in
Australia.
Studies have shown that approximately 50%
of axSpA patients treated with a TNFi achieve an
Assessment in SpondyloArthritis International
Society 40% improvement (ASAS40) [59].
Numerous studies have shown that baseline
MRI positivity and/or elevated CRP is very
important in predicting the response of patients
with axSpA to TNFi [55, 56, 60]. Some studies
even showed no significant difference from
placebo in those with normal CRP and negative
MRI. Predictors for a good response to TNFi
include male gender, low Bath Ankylosing
Spondylitis Functional Index (BASFI), raised
CRP, shorter disease duration, HLA-B27 posi-
tivity and MRI changes [29, 61–63]. Ten-year
drug survival for bDMARDs in axSpA has been
reported to be 49% of treated patients [64].
Predictors of longer drug survival in this study
were male gender, high CRP, and normalisation
of CRP and resolution of MRI inflammation
with TNFi.
Switching bDMARDs for those who have
inadequate response to their first biologic has
also become established in routine clinical care.
The efficacy rates of subsequent bDMARDs are
generally reduced, as shown in the Danish
DANBIO registry, where the mean reduction in
the Bath Ankylosing Spondylitis Disease Activ-
ity Index (BASDAI) at 6 months was 3 units for
the index bDMARD, compared to 1.5 BASDAI
units for the 3rd bDMARD [65]. Drug survival
for sequential bDMARDs also follows a similar
pattern with one study reporting the mean drug
survival for the index bDMARD being 10.2 years
compared to 5.5 years for the second [66]. The
best switching strategy for biologics in axSpA
remains unclear, with no randomised trials to
inform this decision.
Unlike the situation in RA, stopping
bDMARDs is not advisable in stable good
responders with axSpA as most patients stop-
ping TNFi will have a flare of their axSpA within
1 year [67]. However, dose optimisation of TNFi
is becoming common place in routine clinical
care and appears to be a viable approach, with a
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Table 1 Biological DMARD trials in nr-axSpA
Drug Drug
mechanism
Inclusion criteria Patient no.
(active/placebo)
Primary
endpoint
ASAS40
outcome
active/placebo
(%)
LDA/
remission
rate
Adalimumab
(56)
TNF
inhibitor
2009 ASAS axSpA
criteria but not meet
AS criteria
No restriction on
disease duration
BASDAI C 4
Total back pain C 4
91/94 ASAS40
response at
week 12
36%/15%
Golimumab
(55)
TNF
inhibitor
2009 ASAS axSpA
criteria but not meet
AS criteria
Disease
duration B 5 years
BASDAI C 4
Total back pain C 4
98/100 ASAS20
response at
week 16
57%/23%
Certolizumab
(58)
TNF
inhibitor
2009 ASAS axSpA
criteriaa
BASDAI C 4
Total back pain C 4
No restriction on
disease duration
Elevated CRP or
ASAS/OMERACT
MRI changes
147a/107 ASAS 20
response at
week 12
47–48%/16%
Etanercept
(57)
TNF
inhibitor
2009 ASAS axSpA
criteria but not meet
AS criteria.
Disease
duration[ 3 months
and\ 5 years
BASDAI C 4
106/109 ASAS40
response at
week 12
32%/16%
CRP C-reactive protein, MRI magnetic resonance imaging; ‘ASAS/OMERACT MRI’ MRI changes meeting the ASAS/
OMERACT deﬁnition of sacroiliitis, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, LDA low disease
activity
a This trial included both AS and nr-axSpA, but only the nr-axSpA results are reported in the table
170 Rheumatol Ther (2019) 6:165–177
recent study showing that 58% of axSpA
patients were able to reduce dose at 1 year [68].
The ideal combination and timing of initia-
tion with NSAIDs and bDMARDs to prevent
radiographic progression of axSpA need further
evaluation. There is some evidence that TNFi
inhibit radiographic progression in AS; how-
ever, the slow progression of spinal radio-
graphic change in axSpA makes demonstrating
this change logistically challenging [69–71].
Reassuringly, after nearly 2 decades of bDMARD
use in rheumatology, there are no significant or
new safety signals that have become apparent.
While the TNFi have transformed the man-
agement of axSpA, there remains significant
unmet need for this chronic, lifelong condition.
A significant number of patients fail to respond
to or tolerate their first TNFi, while of those who
do respond, many only have a partial response
or lose efficacy over time. Therefore, there
remains a need for treatments in axSpA beyond
those targeting TNF.
FUTURE THERAPY IN NR-AXSPA: IL-
17, IL-23 AND KINASE INHIBITORS
The TNFi were initially developed for RA and
subsequently adopted and shown to be effica-
cious for a range of immune-mediated inflam-
matory diseases, including AS and nr-axSpA.
However, the clinical picture in axSpA is dis-
tinct from that in RA, with the musculoskeletal
picture characterised by enthesitis and axial
involvement, rather than synovitis, and the
presence of characteristic extra-articular mani-
festations, such as psoriasis, uveitis and
inflammatory bowel disease (IBD), shared with
the other SpA conditions but not with RA.
Genome-wide association studies, tissue analy-
sis and preclinical models have identified the
key role of the IL-23/-17 pathway in the
pathogenesis of SpA, including axSpA. Thera-
pies targeting this pathway in psoriasis have led
to remarkable improvements, in excess of those
seen with TNF inhibitors. These therapies were
therefore also tested across the SpA spectrum,
starting initially in psoriatic arthritis (PsA),
where they demonstrated similar levels of effi-
cacy to those seen with TNFi and are now
established in clinical practice for these condi-
tions, although they have not achieved the
same levels of high hurdle response seen in the
skin.
As a result of the distinct regulatory licensing
requirements for AS and nr-axSpA, newer agents
were first tested by the relevant pharmaceutical
manufacturers in patients with active AS. The
fact that nr-axSpA and AS are part of the axSpA
spectrum, rather than distinct conditions, and
the evidence from TNFi suggest that the results
and lessons learnt from AS can be applied to nr-
axSpA. We therefore present the key studies of
agents targeting the IL-23/-17 pathway in AS
and comment on the likely implications of
these results for nr-axSpA.
The efficacy and safety of secukinumab, an
anti-IL-17A monoclonal antibody, for the
treatment of active AS was demonstrated for
secukinumab 150 mg in two phase 3 ran-
domised controlled trials [72]. The MEASURE 1
and 2 studies differed in the secukinumab
loading regimen, being intravenous and sub-
cutaneous, respectively. In both studies, the
primary endpoint of ASAS 20% improvement
(ASAS20) at week 16 was achieved by 61% of the
secukinumab 150 mg group compared to
28–29% of the placebo group. Post hoc analysis
of the MEASURE 2 study indicated that ASAS20
response rates at week 16 for secukinumab
150 mg were 68% in TNFi-naı¨ve patients and
50% for those with previous TNFi exposure [73].
Secukinumab also resulted in improved patient-
reported disease outcomes and health-related
quality of life, which were sustained over 3 years
with high retention rates [74–76]. Significantly,
secukinumab treatment led to low radiographic
progression on radiographs and regression of
spinal inflammation on MRI [75, 77]. As a result
of these studies, secukinumab has been widely
licensed for the treatment of active AS.
Ixekizumab, another IL-17A antagonist, has
subsequently also demonstrated efficacy in
active AS in both a placebo-controlled phase 3
study in biologic-naı¨ve patients and a placebo-/
active-controlled phase 3 study in patients with
prior inadequate response or intolerance to
TNFi [78, 79]. Reassuringly, there were no new
safety signals in the phase 3 studies of secuk-
inumab or ixekizumab in AS beyond those seen
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with previous indications. There are currently
ongoing phase 3 studies of secukinumab (Clin-
icalTrials.gov NCT02696031) and ixekizumab
(ClinicalTrials.gov NCT02757352) in nr-axSpA.
Anti-IL-23 therapies have also been tested in
AS following the suggestive pathogenetic role of
IL-23 and the success of IL-23 inhibition in
psoriasis and PsA. However, in contrast to IL-
17A inhibition, anti-IL-23 therapy with both
p40 IL-23 (ustekinumab) and p19 IL-23 (risan-
kizumab) inhibitors failed to demonstrate effi-
cacy in phase 3 studies in axSpA and a phase 2
study in AS, respectively [80–82]. These initially
surprising results are not fully understood and
warrant further investigation; they may reflect
tissue-discrete pathways, IL-23-independent IL-
17 responses in the spine or other, as yet poorly
understood, mechanisms [82]. Taken together,
these data suggest that, in contrast to IL-17A
blockade, IL-23 inhibition is not an effective
strategy for the treatment of AS and is unlikely
to be taken further for nr-axSpA, although a
phase 2/3 study of tildrakizumab, another p19
IL-23 inhibitor, is still listed as active (Clini-
calTrials.gov NCT03552276).
Small molecule inhibitors, and Janus kinase
(JAK) inhibitors in particular, are entering the
market for a number of immune-mediated
inflammatory diseases, including RA, IBD and
PsA. A 12-week phase 2 study of tofacitinib, an
oral JAK 1/3 inhibitor, in patients with active AS
suggested efficacy, including improvement of
MRI endpoints, with similar safety profile
reported for other conditions [83]. A phase 3
study of tofacitinib in AS is ongoing (Clini-
calTrials.gov NCT03502616). A phase 2 study of
filgotinib, a highly selective JAK 1 inhibitor,
also recently reported achieving the primary
endpoint in patients with active AS, with sig-
nificant improvements also observed for most
secondary and patient-reported outcomes [84].
A phase 2/3 study of upadacitinib, another
selective JAK 1 inhibitor, is also underway in AS
(ClinicalTrials.gov NCT03178487). These
promising phase 2 studies require evaluation in
a robust phase 3 programme, ideally also
including active comparators. The optimal dose
and selectivity of JAK inhibition in SpA remain
to be determined [85]. There are currently no
studies of JAK inhibitors for the treatment of nr-
axSpA registered but are likely to follow if phase
3 studies in AS are successful.
The identification of the important role of
the microbiome in AS is also an area of active
research [86] and there may well be future
therapeutics developed to target the resident
microbiome in nr-axSpA patients. Many
researchers in the axSpA field believe that
intestinal dysbiosis is the genesis of axSpA, so
therapies targeting this area may even have the
potential to prevent development of the full
axSpA phenotype in the future [87]. With the
strong genetic association of aminopeptidase
genes ERAP1 and ERAP2 with AS, there are also
active efforts underway to develop small mole-
cule inhibitors of endoplasmic reticulum
aminopeptidases to trial in axSpA [88].
In summary, advances in imaging have
allowed the identification of disease much ear-
lier in the course of patient symptoms. This has
allowed classification and diagnosis of nr-
axSpA, but there is much further work required
in these areas, especially in imaging definitions.
NSAIDs and physiotherapy remain core first-
line therapy, while biologics have transformed
the treatment paradigm of patients with severe
and active disease axSpA. The biologic and tar-
geted therapies licensed for nr-axSpA are cur-
rently limited to TNF inhibitors. However, the
success of IL-17A inhibitors and promising early
phase results of JAK inhibitors in AS suggest that
these are likely to join the armamentarium for
nr-axSpA in the future. The future is very
exciting for both diagnostic imaging and ther-
apeutics in nr-axSpA.
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